Abstract

REVVITY INC will report first-quarter results on May 5, 2026 Pre-Market; consensus currently points to revenue of 703.31 million US dollars and adjusted EPS of 1.02, with investors watching margin trajectory, software-led growth, and post–year-end order patterns following the company’s February guidance.

Market Forecast

For the first quarter of 2026, the market expects REVVITY INC to generate revenue of 703.31 million US dollars, up 6.37% year over year, adjusted EPS of 1.02, up 7.06% year over year, and EBIT of 163.06 million US dollars, down 2.74% year over year. Forecasts do not include explicit gross margin or net margin targets, so the focus remains on top-line resilience, conversion of the early-year order book, and maintaining operating discipline to protect earnings.

The main business remains anchored by two roughly equal engines: Diagnostics and Life Sciences. The most promising near-term catalyst sits in software-enabled workflows within Life Sciences, supported by the April launch of Signals BioDesign; last quarter Life Sciences revenue was 381.99 million US dollars, and Diagnostics revenue was 390.07 million US dollars.

Last Quarter Review

In the fourth quarter of 2025, REVVITY INC posted revenue of 772.06 million US dollars (up 5.85% year over year), a gross profit margin of 54.62%, GAAP net profit attributable to shareholders of 98.36 million US dollars, a net profit margin of 12.74%, and adjusted EPS of 1.70 (up 19.72% year over year).

A key highlight was execution versus expectations: adjusted EPS exceeded consensus by 0.15, and reported revenue surpassed expectations by 10.77 million US dollars, reflecting solid close rates into year-end. Operationally, both Diagnostics and Life Sciences contributed at near parity, with Diagnostics at 390.07 million US dollars and Life Sciences at 381.99 million US dollars, underscoring balanced exposure across consumables, instruments, and software-led offerings.

Current Quarter Outlook

Main business performance in Q1 2026

REVVITY INC enters the quarter with a measured set of expectations: a modest top-line step-down from the seasonally strong fourth quarter but a year-over-year increase to 703.31 million US dollars, paired with mid-single-digit EPS growth to 1.02. Diagnostics, at 390.07 million US dollars last quarter, should benefit from stable recurring consumables and services activity, while instrument placements typically moderate in early quarters; the resultant mix typically favors gross margin stability, which helps earnings quality even as EBIT is forecast to decline year over year. Life Sciences posted 381.99 million US dollars last quarter and remains supported by demand for consumables and reagents tied to research workflows; the quarter’s cadence often depends on purchasing cycles at biopharma and academic customers, which tend to normalize post-year-end.

The company’s February full-year outlook for revenue of 2.96–2.99 billion US dollars and adjusted EPS of 5.35–5.45 implies a steady execution track across 2026. Translating that high-level view into the current quarter suggests management expects early-year volumes to set a base for the rest of the year, while cost control and product mix help preserve EPS. With consensus modeling EBIT down 2.74% year over year, investors will focus on whether operating leverage from service and software can counterbalance any instrument timing effects, sustaining the quarter’s EPS progress despite lower EBIT growth.

The mix of revenue streams matters this quarter: software and services carry attractive margins and, when combined with steady consumables, can counter softness in instrument cycles. This is particularly relevant in Q1, where order timing can shift to later quarters; resilient recurring revenue is a natural hedge. Any signal that recurring revenue grew faster than the corporate average would be read favorably for the remainder of 2026.

Most promising business: Software-enabled workflows in Life Sciences

The April 9, 2026 launch of Signals BioDesign highlights REVVITY INC’s ongoing expansion in software for biologics research workflows, a strategic area that enhances the productivity of customer R&D teams and integrates with broader informatics suites. While not broken out as a standalone revenue line, software growth can enhance both gross and operating margins due to high incremental profitability and subscription-like characteristics. The ability to cross-sell new capabilities into existing Life Sciences customer bases, including users of Signals and adjacent platforms, is an important growth lever through 2026.

From a practical standpoint, the near-term opportunity is twofold: conversion of pilot deployments into paid seats and enterprise agreements, and incremental attachment to instrument and consumable sales as software becomes a core part of standardized lab workflows. This attachment dynamic tends to improve customer lifetime value, tighten retention, and reduce revenue volatility across cycles. If adoption of Signals BioDesign proceeds as intended, bookings in Q1 and early Q2 could support stronger software revenue contribution in the second half of the year, providing a positive read-through for both growth and margins.

The key to monetization is integration across data capture, analysis, and collaboration within biologics development. Customers seek streamlined, interoperable workflows; addressing this need can reduce implementation friction and shorten sales cycles. As such, even modest software traction can disproportionately lift margins relative to top-line contribution, a dynamic that investors will monitor closely in this print and in the company’s commentary.

Key stock-price drivers this quarter

Margin trajectory is front and center. In Q4 2025, gross margin stood at 54.62%, and net margin at 12.74%. While the market lacks a formal Q1 margin forecast, consensus expects an EPS increase with EBIT down year over year, implying that mix and cost discipline will be the swing factors. If software and services outpace the corporate average and supply-chain costs remain stable, margin commentary could surprise positively, supporting the stock even if revenue lands near the midpoint of expectations.

Guidance quality and tone will also drive the share reaction. With full-year revenue guided to 2.96–2.99 billion US dollars and adjusted EPS to 5.35–5.45 as of early February, any reiteration with constructive color on demand by end-market would be reassuring. Conversely, a cautious or deferral-oriented tone—especially around instrument placements—could overshadow a small revenue or EPS beat. In prior quarters, the market has rewarded clarity on book-to-bill, backlog health, and cadence across the year; similar specificity would help frame the degree to which Q1 sets a conservative or aggressive bar for subsequent quarters.

Lastly, sell-side positioning can exert short-term influence. In April, Barclays shifted to Equalweight with a 95 US dollars target, while Evercore ISI maintained Outperform with a 108 US dollars target in early April after earlier constructive updates in February. A positive print that aligns with consensus and underscores software momentum would likely validate the more constructive view, whereas evidence of slower order conversion could reinforce neutral stances. How management frames the timing of software monetization and instrument demand normalization may be decisive for sentiment into the next quarter.

Analyst Opinions

Across articles published between January 1, 2026 and April 28, 2026, the majority of directional views skew bullish. Counting only directional calls, approximately 67% are bullish versus 33% bearish. On the constructive side, Evercore ISI maintained an Outperform rating on April 6, 2026 and set a 108 US dollars price target, emphasizing improving execution following better-than-expected fourth-quarter results and reinforcing a thesis that software and services can provide margin durability even as instrumentation remains cyclical. Earlier on February 3, 2026, Evercore ISI also raised its target to 118 US dollars, aligning with a post-earnings step-up in estimates, and Barclays lifted its target to 118 US dollars on the same date as models were recalibrated after the beat-and-raise tone.

The bullish case coalesces around several themes. First, the fourth-quarter beat—adjusted EPS of 1.70 versus 1.55 expected and revenue outperformance of 10.77 million US dollars—suggests that commercial execution and mix management are gaining traction. Such performance provides a higher-confidence baseline for 2026 modeling. Second, the new software release, Signals BioDesign, extends the company’s capabilities in biologics research workflows; this category typically carries favorable profitability and creates optionality for cross-selling within existing enterprise relationships. Bulls argue that even incremental software adoption can protect margins in the face of near-term volatility in hardware or macro-sensitive purchasing. Third, the full-year guide provided in early February—revenue of 2.96–2.99 billion US dollars and adjusted EPS of 5.35–5.45—sits modestly ahead of prior street models, which supports the view that Q1 is more a foundation-setting quarter than a destination, with momentum expected to build through the year.

Supportive commentary from institutions reinforces this stance. Evercore ISI’s maintained Outperform in April—despite trimming the target to 108 US dollars—signals confidence in the structural mix upgrade from software and services, as well as the durability of consumables demand. The argument is that if Q1 lands near consensus—revenue of 703.31 million US dollars (+6.37% year over year) and EPS of 1.02 (+7.06% year over year)—and management reiterates full-year guardrails with constructive color on demand normalization, the stock’s risk-reward tilts favorable as the year progresses. Even with Barclays’ April downgrade to Equalweight and a 95 US dollars target, bulls see this as a calibration to near-term uncertainty rather than a thesis break, given that February price target increases came on the heels of tangible upside to Q4 numbers and a guide that modestly exceeded prevailing estimates.

Ultimately, the majority view anticipates that REVVITY INC can deliver an in-line to slightly better-than-expected quarter on revenue and EPS, with balanced commentary on margins and execution. The strongest version of the bullish argument would be supported by: confirmation that recurring revenue grew at or above the corporate average; early evidence of customer uptake for Signals BioDesign within Life Sciences accounts; and a reiteration of the full-year revenue and EPS ranges from February. If these elements materialize, the path to consensus second-quarter and full-year numbers looks credible, providing a constructive setup into the next update cycle.